| Publications | PubMed=978138; DOI=10.1084/jem.144.4.873
Shiku H., Takahashi T., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
J. Exp. Med. 144:873-881(1976) PubMed=1067619; DOI=10.1073/pnas.73.9.3278
Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F., Old L.J.
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976) PubMed=313568; DOI=10.1073/pnas.76.6.2898
Carey T.E., Lloyd K.O., Takahashi T., Travassos L.R., Old L.J.
AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.
Proc. Natl. Acad. Sci. U.S.A. 76:2898-2902(1979) PubMed=6933476; DOI=10.1073/pnas.77.7.4260
Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F., Old L.J.
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980) DOI=10.1007/978-1-4615-7228-2_39
Houghton A.N., Oettgen H.F., Old L.J.
Malignant melanoma. Current status of the search for melanoma-specific antigens.
(In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981) PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=7175440; DOI=10.1084/jem.156.6.1755
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982) PubMed=6864164; DOI=10.1084/jem.158.1.53
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984) PubMed=2983346; DOI=10.1073/pnas.82.5.1470
Dracopoli N.C., Houghton A.N., Old L.J.
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=2784858; DOI=10.1073/pnas.86.8.2804
Knuth A., Wolfel T., Klehmann E., Boon T., Meyer zum Buschenfelde K.-H.
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989) PubMed=7652577; DOI=10.1126/science.7652577
Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Buschenfelde K.-H., Beach D.H.
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
Science 269:1281-1284(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011) PubMed=21725359; DOI=10.1038/onc.2011.250
Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|